12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Deals

Shire, ViroPharma deal

ViroPharma disclosed in an SEC filing details of the discussions it had with Shire related to Shire's plans to acquire ViroPharma for $50 per share in cash, which the companies said values ViroPharma at $4.2 billion. The price is a 27% premium to ViroPharma's close of $39.38 on Nov. 8, before the deal was announced, and a 64% premium to ViroPharma's close of $30.47 on Sept. 12, before the company jumped on rumors of a possible auction after...

Read the full 368 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >